EGFR-immunohistochemistry in colorectal cancer and non-small cell lung cancer: Comparison of 3 commercially available EGFR-antibodies

Acta Gastro-Enterologica Belgica

Volumn 71, Issue 2, 2008, Pages 213-218

  Buffet, W ^a   Geboes, K P ^a   Dehertogh, G ^a   Geboes, K ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY;

ARTICLE; CANCER CELL; COLORECTAL CANCER; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MOLECULAR CLONING; PROTEIN EXPRESSION; SCORING SYSTEM;

ANTIBODIES, NEOPLASM; BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; COLORECTAL NEOPLASMS; EPIDERMAL GROWTH FACTOR; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 47149092640     PISSN: 00015644     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. ARTEAGA C.L. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin. Oncol., 2002 Oct, 29 (5 Suppl 14) : 3-9.
2. DIASIO R.B., FOURIE J. Targeting the epidermal growth factor receptor in the treatment of colorectal cancer : state of the art. Drugs, 2006, 66 (11) : 1441-63.
3. ITALIANO A. Targeting the epidermal growth factor receptor in colorectal cancer : advances and controversies. Oncology, 2006, 70 (3) : 161-7.
4. CUNNINGHAM D., HUMBLET Y., SIENA S., KHAYAT D., BLEIBERG H., SANTORO A., BETS D., MUESER M., HARSTRICK A., VERSLYPE C., CHAU I., VAN CUTSEM E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med., 2004 Jul. 22, 351 (4) : 337-45.
5. CHUNG K.Y., SHIA J., KEMENY N.E., SHAH M., SCHWARTZ G.K., TSE A., HAMILTON A., PAN D., SCHRAG D., SCHWARTZ L., KLIMSTRA D.S., FRIDMAN D., KELSEN D.P., SALTZ L.B. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the EGFR by immunohistochemistry. J. Clin. Oncol., Mar. 2005, 23 (9) : 1803-1810.
6. DEI TOS A.P., ELLIS I. Assessing epidermal growth factor receptor expression in tumours : what is the value of current test methods ? Eur. J. Cancer, 2005 Jul., 41 (10) : 1383-92.
7. LEONG A.S. Pitfalls in Diagnostic Immunology. Adv. Anat. Pathol., 2004 Mar., 11 (2) : 86-93.
8. RAMOS-VARA J.A. Technical aspects of immunohistochemistry. Vet. Pathol., 2005 Jul, 42 (4) : 405-26.
9. BHARGAVA R., CHEN B., KLIMSTRA D.S., SALTZ L.B., HEDVAT C., TANG L.H.,GERALD W., TERUYA-FELDSTEIN J., PATY P.B., QIN J., SHIA J. Comparison of two antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in colorectal carcinomas, adenomas, and normal mucosa. Cancer, 2006 Apr 15, 106 (8) : 1857-62.
10. PENAULT-LLORCA F., CAYRE A., ARNOULD L., BIBEAU F., BRALET M.P., ROCHAIX P., SAVARY J.., SABOURIN J.C. Is there an immunohistochemical technique definitively valid in epidermal growth factor receptor assessment ? Oncol. Rep., 2006 Dec., 16 (6) : 1173-1179.
11. SPAULDING D.C., SPAULDING B.O. Epidermal growth factor receptor expression and measurement in solid tumors. Semin. Oncol., 2002 Oct., 29 (5 Suppl 14) : 45-54.
12. LANDIS J., KOCH G. The measurement of observer agreement for categorical data. Biometrics, 1977, 33 : 159-174.
13. HAUSTERMANS K., FOWLER F., GEBOES K., LERUT T., VAN DER SCHUEREN E. Do cell kinetics have prognostic and/or predictive value in oesophageal cancer treated by surgery? Eur. J. Surg. Oncol., 1997 Aug., 23 (4) : 293-297.
14. BRABLETZ T., JUNG A., REU S., PORZNER M., HLUBEK F., KUNZSCHUGHART L.A. Variable beta-catenin expression in colorectal cancers indicates tumour progression driven by the tumor environment. Proc. Natl. Acad. Sci. USA, 2001 Aug., 98 (18) : 10356-10361.
15. PERSONENI N., DE HERTOGH G., STÖRKEL S., DEBIECRYCHTER M., DE ROOCK W., GEBOES K., PIESSEVAUX H., VAN CUTSEM E., TEJPAR S. Outcome prediction to cetuximab-based therapy in advanced colorectal cancer : analysis of EGFR and HER2 gene copy number by fluorescence in situ hybridisation. J. Clin. Oncol., 2007, 25 (185) : 10569.
16. ZLOBEC I., TERRACCIANO L., JASS J.R., LUGLI A. Value of staining intensity in the interpretation of immunohistochemistry for tumor markers in colorectal cancer. Virchows Arch., 2007, 451 : 763-769.
17. BUCKLEY A.F., KAKAR S. Comparison of the Dako EGFR pharmDx Kit and Zymed EGFR antibody for assessment of EGFR status in Colorectal adenocarcinoma. Appl. Immunohistochem. Mol. Morphol., 2007, 15 : 305-309.
18. ATKINS D., REIFFEN K.A., TEGTMEIER C.L., WINTHER H., BONATO M.S., STORKEL S. Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues : variation in staining intensity due to choice of fixative and storage time of tissue sections. J. Histochem. Cytochem., 2004 Jul., 52 (7) : 893-901.
19. DERECSKEI K., MOLDVAY J., BOGOS K., TIMAR J. Protocol modifications influence the result of EGF receptor immunodetection by EGFR pharmDx in paraffin-embedded cancer tissues. Pathol. Oncol. Res., 2006, 12 (4) : 243-6.